Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Leukemia, Myeloid, Acute | 168 | 2024 | 763 | 14.690 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 66 | 2023 | 173 | 10.130 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 73 | 2024 | 375 | 9.460 |
Why?
|
Antineoplastic Agents | 110 | 2023 | 2360 | 6.490 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 135 | 2024 | 2438 | 6.180 |
Why?
|
Hematopoietic Stem Cell Transplantation | 66 | 2023 | 878 | 5.950 |
Why?
|
Leukemia, Myeloid | 71 | 2016 | 249 | 5.510 |
Why?
|
Pyrimidines | 50 | 2021 | 370 | 4.990 |
Why?
|
Protein Kinase Inhibitors | 39 | 2023 | 589 | 4.670 |
Why?
|
Neoplasms, Second Primary | 27 | 2022 | 252 | 4.250 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 31 | 2021 | 136 | 4.070 |
Why?
|
Piperazines | 42 | 2015 | 272 | 4.010 |
Why?
|
Cytarabine | 77 | 2023 | 218 | 3.920 |
Why?
|
fms-Like Tyrosine Kinase 3 | 36 | 2023 | 127 | 3.840 |
Why?
|
Myelodysplastic Syndromes | 53 | 2020 | 346 | 3.660 |
Why?
|
Remission Induction | 97 | 2024 | 722 | 3.590 |
Why?
|
Fusion Proteins, bcr-abl | 35 | 2023 | 107 | 3.510 |
Why?
|
Chromosome Aberrations | 55 | 2022 | 387 | 3.060 |
Why?
|
Imatinib Mesylate | 50 | 2021 | 126 | 3.060 |
Why?
|
Leukemia, Myeloid, Chronic-Phase | 18 | 2023 | 24 | 2.840 |
Why?
|
Leukemia, Promyelocytic, Acute | 16 | 2022 | 49 | 2.800 |
Why?
|
Humans | 555 | 2024 | 86643 | 2.570 |
Why?
|
Adult | 302 | 2024 | 25648 | 2.530 |
Why?
|
Middle Aged | 310 | 2022 | 25028 | 2.500 |
Why?
|
Aged | 268 | 2023 | 18415 | 2.440 |
Why?
|
Mutation | 63 | 2023 | 3968 | 2.400 |
Why?
|
Treatment Outcome | 149 | 2023 | 7993 | 2.150 |
Why?
|
Disease-Free Survival | 74 | 2023 | 1204 | 2.130 |
Why?
|
Staurosporine | 7 | 2022 | 33 | 2.040 |
Why?
|
Vidarabine | 27 | 2015 | 141 | 2.020 |
Why?
|
Prognosis | 113 | 2023 | 3679 | 1.970 |
Why?
|
Female | 315 | 2023 | 44532 | 1.910 |
Why?
|
Male | 319 | 2023 | 40965 | 1.910 |
Why?
|
Leukemia | 35 | 2022 | 320 | 1.890 |
Why?
|
MicroRNAs | 26 | 2016 | 534 | 1.880 |
Why?
|
Survival Analysis | 72 | 2020 | 1538 | 1.870 |
Why?
|
Benzamides | 42 | 2015 | 229 | 1.820 |
Why?
|
Daunorubicin | 34 | 2023 | 78 | 1.810 |
Why?
|
Transplantation Conditioning | 27 | 2021 | 373 | 1.770 |
Why?
|
Survival Rate | 62 | 2021 | 1863 | 1.740 |
Why?
|
Aged, 80 and over | 111 | 2021 | 6509 | 1.690 |
Why?
|
Gene Expression Regulation, Leukemic | 25 | 2018 | 90 | 1.640 |
Why?
|
Adolescent | 129 | 2024 | 8981 | 1.620 |
Why?
|
Transplantation, Homologous | 43 | 2021 | 996 | 1.610 |
Why?
|
Dasatinib | 14 | 2021 | 37 | 1.600 |
Why?
|
Consolidation Chemotherapy | 6 | 2018 | 22 | 1.540 |
Why?
|
Translocation, Genetic | 39 | 2021 | 265 | 1.460 |
Why?
|
Arabinonucleosides | 7 | 2013 | 39 | 1.420 |
Why?
|
Drug Administration Schedule | 43 | 2019 | 916 | 1.370 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2023 | 44 | 1.310 |
Why?
|
Antibodies, Monoclonal | 20 | 2010 | 1376 | 1.310 |
Why?
|
Hematologic Neoplasms | 15 | 2023 | 329 | 1.300 |
Why?
|
Young Adult | 74 | 2024 | 5976 | 1.260 |
Why?
|
Drug Resistance, Neoplasm | 28 | 2022 | 592 | 1.230 |
Why?
|
Neoplasm Recurrence, Local | 17 | 2023 | 1313 | 1.230 |
Why?
|
Follow-Up Studies | 51 | 2022 | 3640 | 1.230 |
Why?
|
Protein-Tyrosine Kinases | 14 | 2022 | 302 | 1.220 |
Why?
|
Aminoglycosides | 9 | 2014 | 32 | 1.220 |
Why?
|
Acute Disease | 67 | 2022 | 826 | 1.200 |
Why?
|
Nuclear Proteins | 16 | 2020 | 696 | 1.150 |
Why?
|
Philadelphia Chromosome | 9 | 2021 | 38 | 1.130 |
Why?
|
Sarcoma, Myeloid | 4 | 2015 | 15 | 1.130 |
Why?
|
Tandem Repeat Sequences | 7 | 2021 | 26 | 1.120 |
Why?
|
Chromosomes, Human, Pair 5 | 19 | 2021 | 109 | 1.120 |
Why?
|
Gene Expression Profiling | 32 | 2016 | 1384 | 1.110 |
Why?
|
Azacitidine | 11 | 2023 | 137 | 1.060 |
Why?
|
Clinical Trials as Topic | 26 | 2022 | 1169 | 1.020 |
Why?
|
Lymphoma | 9 | 2023 | 262 | 1.000 |
Why?
|
Biomarkers, Tumor | 22 | 2021 | 1464 | 0.990 |
Why?
|
Immunotherapy | 10 | 2023 | 629 | 0.980 |
Why?
|
Central Nervous System Neoplasms | 4 | 2018 | 81 | 0.980 |
Why?
|
Salvage Therapy | 13 | 2021 | 233 | 0.950 |
Why?
|
Recurrence | 35 | 2022 | 1139 | 0.950 |
Why?
|
Induction Chemotherapy | 8 | 2019 | 147 | 0.950 |
Why?
|
Lymphoma, T-Cell | 1 | 2023 | 48 | 0.900 |
Why?
|
Asparaginase | 6 | 2023 | 35 | 0.900 |
Why?
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 53 | 0.870 |
Why?
|
Aniline Compounds | 6 | 2023 | 55 | 0.870 |
Why?
|
Antibodies, Neoplasm | 9 | 2010 | 84 | 0.870 |
Why?
|
Age Factors | 31 | 2018 | 1851 | 0.850 |
Why?
|
Graft vs Host Disease | 17 | 2020 | 365 | 0.830 |
Why?
|
Bone Marrow Transplantation | 15 | 2006 | 286 | 0.820 |
Why?
|
Myeloproliferative Disorders | 6 | 2022 | 110 | 0.820 |
Why?
|
Cytosine | 4 | 2018 | 127 | 0.820 |
Why?
|
Antibodies, Monoclonal, Humanized | 23 | 2023 | 930 | 0.810 |
Why?
|
Neoplasm Proteins | 20 | 2012 | 532 | 0.810 |
Why?
|
Antibodies, Bispecific | 5 | 2021 | 21 | 0.800 |
Why?
|
Adenine Nucleotides | 4 | 2013 | 63 | 0.800 |
Why?
|
Disease Management | 9 | 2020 | 327 | 0.780 |
Why?
|
Mitoxantrone | 11 | 2020 | 68 | 0.770 |
Why?
|
Kaplan-Meier Estimate | 32 | 2019 | 860 | 0.760 |
Why?
|
Geriatric Assessment | 5 | 2022 | 166 | 0.750 |
Why?
|
Cladribine | 6 | 2004 | 35 | 0.750 |
Why?
|
Bone Marrow | 37 | 2018 | 435 | 0.750 |
Why?
|
Combined Modality Therapy | 23 | 2021 | 1686 | 0.730 |
Why?
|
Interferon-alpha | 13 | 2017 | 233 | 0.720 |
Why?
|
Cytogenetic Analysis | 18 | 2017 | 71 | 0.710 |
Why?
|
Pyrazines | 5 | 2023 | 92 | 0.700 |
Why?
|
Dose-Response Relationship, Drug | 26 | 2021 | 1961 | 0.680 |
Why?
|
Antimetabolites, Antineoplastic | 10 | 2017 | 236 | 0.670 |
Why?
|
Tretinoin | 10 | 2020 | 126 | 0.660 |
Why?
|
Drugs, Generic | 2 | 2016 | 21 | 0.650 |
Why?
|
Respiratory Tract Infections | 3 | 2015 | 105 | 0.640 |
Why?
|
Intestinal Absorption | 2 | 2017 | 124 | 0.640 |
Why?
|
Valine | 2 | 2016 | 69 | 0.640 |
Why?
|
Acyclovir | 2 | 2016 | 107 | 0.630 |
Why?
|
Chromosome Deletion | 20 | 2014 | 229 | 0.620 |
Why?
|
Genetic Predisposition to Disease | 14 | 2022 | 2271 | 0.610 |
Why?
|
Carbonated Beverages | 1 | 2017 | 2 | 0.610 |
Why?
|
Myeloid-Lymphoid Leukemia Protein | 11 | 2013 | 72 | 0.610 |
Why?
|
Chromosomes, Human, Pair 7 | 9 | 2014 | 79 | 0.610 |
Why?
|
Precision Medicine | 2 | 2019 | 395 | 0.600 |
Why?
|
Herpes Zoster | 3 | 2016 | 78 | 0.600 |
Why?
|
Drug Monitoring | 5 | 2021 | 118 | 0.590 |
Why?
|
Immunotoxins | 4 | 2012 | 14 | 0.590 |
Why?
|
Rituximab | 12 | 2021 | 116 | 0.590 |
Why?
|
Medical Oncology | 4 | 2021 | 359 | 0.590 |
Why?
|
Neoplasms, Radiation-Induced | 2 | 2012 | 109 | 0.580 |
Why?
|
Organophosphonates | 1 | 2016 | 50 | 0.570 |
Why?
|
Herpesvirus 3, Human | 1 | 2016 | 43 | 0.570 |
Why?
|
Proton Pump Inhibitors | 2 | 2017 | 31 | 0.570 |
Why?
|
DNA-Binding Proteins | 20 | 2016 | 1208 | 0.570 |
Why?
|
Stem Cell Transplantation | 10 | 2020 | 183 | 0.560 |
Why?
|
Drugs, Investigational | 1 | 2016 | 37 | 0.560 |
Why?
|
Leukemia, Radiation-Induced | 2 | 2015 | 14 | 0.560 |
Why?
|
Prospective Studies | 33 | 2022 | 4213 | 0.560 |
Why?
|
Proto-Oncogene Proteins | 15 | 2018 | 645 | 0.550 |
Why?
|
Neoplasm, Residual | 8 | 2022 | 162 | 0.540 |
Why?
|
Etoposide | 15 | 2013 | 196 | 0.540 |
Why?
|
Maintenance Chemotherapy | 4 | 2021 | 76 | 0.530 |
Why?
|
Karyotyping | 41 | 2014 | 250 | 0.530 |
Why?
|
Oxides | 3 | 2014 | 43 | 0.520 |
Why?
|
Neutropenia | 10 | 2010 | 215 | 0.520 |
Why?
|
Quality of Life | 8 | 2022 | 1585 | 0.520 |
Why?
|
Piperidines | 7 | 2021 | 181 | 0.520 |
Why?
|
Arsenicals | 3 | 2014 | 48 | 0.520 |
Why?
|
Thrombocytopenia | 9 | 2017 | 183 | 0.520 |
Why?
|
Time Factors | 35 | 2015 | 5210 | 0.510 |
Why?
|
Models, Economic | 1 | 2015 | 60 | 0.510 |
Why?
|
Neoplasms | 13 | 2022 | 2898 | 0.510 |
Why?
|
Molecular Targeted Therapy | 3 | 2018 | 266 | 0.510 |
Why?
|
Multivariate Analysis | 22 | 2020 | 999 | 0.500 |
Why?
|
Thiazoles | 9 | 2013 | 131 | 0.500 |
Why?
|
Polyethylene Glycols | 5 | 2023 | 363 | 0.490 |
Why?
|
Isocitrate Dehydrogenase | 3 | 2023 | 51 | 0.490 |
Why?
|
Drug Resistance, Multiple | 4 | 2008 | 20 | 0.490 |
Why?
|
Antiviral Agents | 2 | 2016 | 510 | 0.480 |
Why?
|
Alemtuzumab | 13 | 2014 | 83 | 0.480 |
Why?
|
Abnormal Karyotype | 2 | 2013 | 8 | 0.470 |
Why?
|
Positron Emission Tomography Computed Tomography | 1 | 2014 | 86 | 0.460 |
Why?
|
Lung Diseases | 2 | 2014 | 263 | 0.460 |
Why?
|
Multiple Myeloma | 2 | 2015 | 307 | 0.450 |
Why?
|
Cord Blood Stem Cell Transplantation | 4 | 2016 | 93 | 0.450 |
Why?
|
Disease Progression | 20 | 2017 | 1531 | 0.450 |
Why?
|
Infusions, Intravenous | 18 | 2014 | 429 | 0.450 |
Why?
|
Chromosomes, Human, Pair 21 | 11 | 2015 | 54 | 0.440 |
Why?
|
Cyclosporins | 6 | 2013 | 59 | 0.440 |
Why?
|
Leukemia, Myeloid, Accelerated Phase | 4 | 2010 | 7 | 0.440 |
Why?
|
Risk Factors | 34 | 2020 | 5417 | 0.440 |
Why?
|
Histamine H2 Antagonists | 1 | 2012 | 15 | 0.430 |
Why?
|
Immunophenotyping | 14 | 2019 | 211 | 0.430 |
Why?
|
Proportional Hazards Models | 18 | 2020 | 859 | 0.430 |
Why?
|
HLA Antigens | 3 | 2021 | 232 | 0.420 |
Why?
|
Aminopyridines | 2 | 2023 | 38 | 0.420 |
Why?
|
Triazines | 2 | 2023 | 53 | 0.410 |
Why?
|
Bortezomib | 3 | 2018 | 76 | 0.410 |
Why?
|
DNA Mutational Analysis | 13 | 2016 | 526 | 0.410 |
Why?
|
Burkitt Lymphoma | 4 | 2014 | 31 | 0.410 |
Why?
|
Leukemia-Lymphoma, Adult T-Cell | 3 | 2007 | 16 | 0.400 |
Why?
|
Methotrexate | 9 | 2015 | 249 | 0.400 |
Why?
|
Chromosomes, Human, Pair 11 | 9 | 2006 | 106 | 0.390 |
Why?
|
Risk Assessment | 15 | 2016 | 2261 | 0.390 |
Why?
|
Mutation, Missense | 3 | 2014 | 276 | 0.390 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 6 | 1993 | 112 | 0.390 |
Why?
|
Blast Crisis | 10 | 2013 | 33 | 0.390 |
Why?
|
Clinical Trials, Phase II as Topic | 9 | 2016 | 176 | 0.390 |
Why?
|
Hematopoietic Stem Cells | 9 | 2016 | 292 | 0.390 |
Why?
|
Antigens, CD | 6 | 2009 | 458 | 0.390 |
Why?
|
Radiotherapy | 8 | 2009 | 328 | 0.390 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 10 | 2014 | 78 | 0.380 |
Why?
|
Leukemia, B-Cell | 5 | 2002 | 23 | 0.380 |
Why?
|
United States | 26 | 2024 | 6672 | 0.380 |
Why?
|
Quinolones | 3 | 2021 | 60 | 0.380 |
Why?
|
Retrospective Studies | 25 | 2024 | 8489 | 0.380 |
Why?
|
Randomized Controlled Trials as Topic | 10 | 2022 | 865 | 0.380 |
Why?
|
Child | 34 | 2023 | 6927 | 0.380 |
Why?
|
RNA, Neoplasm | 5 | 2018 | 87 | 0.380 |
Why?
|
Cytogenetics | 8 | 2022 | 27 | 0.370 |
Why?
|
Interleukin-2 | 5 | 2013 | 249 | 0.370 |
Why?
|
Inflammatory Breast Neoplasms | 2 | 2023 | 4 | 0.360 |
Why?
|
Gene Dosage | 2 | 2012 | 207 | 0.360 |
Why?
|
Myeloid Cells | 1 | 2010 | 98 | 0.360 |
Why?
|
Oncogene Proteins, Fusion | 7 | 2016 | 128 | 0.360 |
Why?
|
Anti-Bacterial Agents | 4 | 2002 | 746 | 0.350 |
Why?
|
Antigens, Differentiation, Myelomonocytic | 4 | 2005 | 32 | 0.350 |
Why?
|
Cyclophosphamide | 12 | 2015 | 299 | 0.350 |
Why?
|
Cell Transformation, Neoplastic | 8 | 2015 | 427 | 0.350 |
Why?
|
Neoplastic Stem Cells | 5 | 2016 | 143 | 0.350 |
Why?
|
Health Status | 1 | 2011 | 360 | 0.350 |
Why?
|
Polymorphism, Genetic | 4 | 2016 | 819 | 0.340 |
Why?
|
Histone Deacetylase Inhibitors | 3 | 2016 | 85 | 0.340 |
Why?
|
Angiogenesis Inhibitors | 2 | 2014 | 311 | 0.330 |
Why?
|
Transplantation, Autologous | 9 | 2019 | 331 | 0.330 |
Why?
|
Enzyme Inhibitors | 5 | 2023 | 639 | 0.330 |
Why?
|
Lymphoma, Non-Hodgkin | 11 | 2011 | 261 | 0.330 |
Why?
|
Adolescent Behavior | 3 | 2001 | 106 | 0.330 |
Why?
|
Cohort Studies | 14 | 2021 | 2767 | 0.330 |
Why?
|
Hodgkin Disease | 8 | 2007 | 177 | 0.320 |
Why?
|
Thrombopoietin | 4 | 2017 | 12 | 0.320 |
Why?
|
Pyrazoles | 3 | 2022 | 153 | 0.320 |
Why?
|
Neoplasm Staging | 15 | 2018 | 1939 | 0.320 |
Why?
|
Hematologic Agents | 3 | 2017 | 4 | 0.320 |
Why?
|
Chromosome Inversion | 9 | 2012 | 47 | 0.320 |
Why?
|
Purine Nucleosides | 1 | 2007 | 7 | 0.320 |
Why?
|
Chromosomes, Human, Pair 16 | 7 | 2004 | 79 | 0.320 |
Why?
|
Purine-Nucleoside Phosphorylase | 1 | 2007 | 23 | 0.320 |
Why?
|
Adenine | 4 | 2021 | 85 | 0.310 |
Why?
|
Pyrimidinones | 1 | 2007 | 36 | 0.310 |
Why?
|
Antigens, CD34 | 9 | 2017 | 158 | 0.310 |
Why?
|
Gene Duplication | 3 | 2020 | 125 | 0.310 |
Why?
|
Oligonucleotide Array Sequence Analysis | 12 | 2012 | 689 | 0.310 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 4 | 2012 | 67 | 0.310 |
Why?
|
Incidence | 11 | 2022 | 1577 | 0.300 |
Why?
|
Polymorphism, Single Nucleotide | 7 | 2021 | 2357 | 0.300 |
Why?
|
Treatment Failure | 8 | 2015 | 285 | 0.300 |
Why?
|
Bone Marrow Cells | 4 | 2014 | 253 | 0.300 |
Why?
|
Cardiac Tamponade | 1 | 2007 | 17 | 0.300 |
Why?
|
Busulfan | 5 | 2015 | 39 | 0.300 |
Why?
|
Trans-Activators | 8 | 2018 | 429 | 0.300 |
Why?
|
Asparagine | 1 | 2007 | 29 | 0.300 |
Why?
|
Granulocyte Colony-Stimulating Factor | 4 | 2016 | 165 | 0.300 |
Why?
|
Feasibility Studies | 5 | 2009 | 751 | 0.290 |
Why?
|
Karyotype | 3 | 2022 | 33 | 0.290 |
Why?
|
Leukemia, T-Cell | 1 | 2006 | 17 | 0.290 |
Why?
|
Gene Rearrangement | 10 | 2012 | 170 | 0.290 |
Why?
|
Transcription Factors | 14 | 2018 | 1565 | 0.290 |
Why?
|
Polymerase Chain Reaction | 9 | 2012 | 927 | 0.290 |
Why?
|
Multicenter Studies as Topic | 8 | 2022 | 159 | 0.280 |
Why?
|
Child Behavior | 2 | 2001 | 48 | 0.280 |
Why?
|
Biological Availability | 4 | 2017 | 92 | 0.280 |
Why?
|
Sulfonamides | 2 | 2021 | 300 | 0.280 |
Why?
|
Maximum Tolerated Dose | 10 | 2017 | 270 | 0.280 |
Why?
|
Carcinogens | 3 | 2002 | 108 | 0.270 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 12 | 2010 | 879 | 0.270 |
Why?
|
Child, Preschool | 18 | 2018 | 3612 | 0.270 |
Why?
|
DNA (Cytosine-5-)-Methyltransferases | 3 | 2018 | 55 | 0.270 |
Why?
|
DNA, Neoplasm | 10 | 2003 | 265 | 0.260 |
Why?
|
Societies, Medical | 3 | 2019 | 572 | 0.260 |
Why?
|
Leukemia, Lymphoid | 6 | 1985 | 72 | 0.260 |
Why?
|
Chromosomes, Human, Pair 8 | 8 | 2015 | 85 | 0.260 |
Why?
|
Chromosome Disorders | 15 | 1999 | 114 | 0.260 |
Why?
|
Administration, Oral | 13 | 2019 | 684 | 0.260 |
Why?
|
Practice Patterns, Physicians' | 3 | 2016 | 582 | 0.260 |
Why?
|
Thionucleotides | 4 | 2021 | 56 | 0.260 |
Why?
|
Mevalonic Acid | 5 | 1984 | 13 | 0.260 |
Why?
|
Tumor Suppressor Proteins | 3 | 2012 | 279 | 0.260 |
Why?
|
Flavonoids | 3 | 2015 | 85 | 0.250 |
Why?
|
Dexamethasone | 3 | 2021 | 326 | 0.250 |
Why?
|
Recombinant Fusion Proteins | 5 | 2017 | 557 | 0.250 |
Why?
|
Melphalan | 5 | 2023 | 98 | 0.250 |
Why?
|
Drug Costs | 2 | 2015 | 62 | 0.250 |
Why?
|
Drug Hypersensitivity | 2 | 1998 | 37 | 0.250 |
Why?
|
Doxorubicin | 10 | 2015 | 295 | 0.250 |
Why?
|
Down-Regulation | 7 | 2016 | 504 | 0.250 |
Why?
|
Risk | 8 | 2014 | 674 | 0.250 |
Why?
|
Allografts | 3 | 2019 | 172 | 0.240 |
Why?
|
Phthalazines | 2 | 2014 | 39 | 0.240 |
Why?
|
Mammary Glands, Human | 1 | 2023 | 22 | 0.240 |
Why?
|
Haplotypes | 3 | 2016 | 642 | 0.230 |
Why?
|
Proto-Oncogene Proteins c-kit | 4 | 2013 | 79 | 0.230 |
Why?
|
Genes, Tumor Suppressor | 4 | 2016 | 157 | 0.230 |
Why?
|
Injections, Subcutaneous | 6 | 2010 | 117 | 0.230 |
Why?
|
Ricin | 1 | 2003 | 6 | 0.230 |
Why?
|
Deoxycytidine | 1 | 2004 | 237 | 0.230 |
Why?
|
Neutrophils | 8 | 2016 | 307 | 0.230 |
Why?
|
Radiation-Sensitizing Agents | 2 | 2014 | 94 | 0.220 |
Why?
|
Pyridines | 3 | 2014 | 310 | 0.220 |
Why?
|
Whole-Body Irradiation | 2 | 2000 | 63 | 0.220 |
Why?
|
Triple Negative Breast Neoplasms | 2 | 2016 | 137 | 0.220 |
Why?
|
Musculoskeletal Pain | 1 | 2022 | 10 | 0.220 |
Why?
|
Bendamustine Hydrochloride | 2 | 2021 | 8 | 0.220 |
Why?
|
Mycoses | 4 | 2007 | 46 | 0.220 |
Why?
|
Lymphatic Vessels | 1 | 2023 | 68 | 0.220 |
Why?
|
Recombinant Proteins | 11 | 2014 | 1014 | 0.220 |
Why?
|
Eosinophils | 4 | 1995 | 194 | 0.220 |
Why?
|
Vincristine | 7 | 2016 | 111 | 0.220 |
Why?
|
Gene Expression Regulation, Neoplastic | 8 | 2013 | 1197 | 0.220 |
Why?
|
Gene Expression | 9 | 2020 | 1284 | 0.210 |
Why?
|
Immunoconjugates | 1 | 2003 | 106 | 0.210 |
Why?
|
Histocompatibility Testing | 4 | 2017 | 154 | 0.210 |
Why?
|
Antigens, Neoplasm | 4 | 2009 | 325 | 0.210 |
Why?
|
Dinitrobenzenes | 1 | 2002 | 5 | 0.210 |
Why?
|
Animals | 19 | 2023 | 26582 | 0.210 |
Why?
|
Tumor Suppressor Protein p53 | 4 | 2018 | 381 | 0.210 |
Why?
|
CCAAT-Enhancer-Binding Proteins | 6 | 2011 | 34 | 0.210 |
Why?
|
Pediatric Obesity | 1 | 2022 | 22 | 0.210 |
Why?
|
Unrelated Donors | 3 | 2017 | 50 | 0.210 |
Why?
|
Escherichia coli | 6 | 2000 | 597 | 0.210 |
Why?
|
Biomedical Research | 1 | 2006 | 376 | 0.210 |
Why?
|
Europe | 8 | 2020 | 309 | 0.210 |
Why?
|
T-Lymphocytes | 6 | 2023 | 1195 | 0.210 |
Why?
|
Surface-Active Agents | 1 | 2002 | 59 | 0.200 |
Why?
|
Socioeconomic Factors | 2 | 2024 | 567 | 0.200 |
Why?
|
Phenotype | 7 | 2019 | 2378 | 0.200 |
Why?
|
Topotecan | 3 | 2009 | 45 | 0.200 |
Why?
|
DNA Damage | 3 | 2013 | 366 | 0.200 |
Why?
|
Sex Characteristics | 1 | 2023 | 319 | 0.200 |
Why?
|
Clonal Evolution | 1 | 2021 | 15 | 0.200 |
Why?
|
Genes, Wilms Tumor | 3 | 2010 | 6 | 0.200 |
Why?
|
Bone Marrow Diseases | 4 | 2009 | 40 | 0.200 |
Why?
|
Agranulocytosis | 2 | 1993 | 20 | 0.200 |
Why?
|
Evidence-Based Medicine | 4 | 2015 | 429 | 0.200 |
Why?
|
Proto-Oncogenes | 6 | 2013 | 61 | 0.200 |
Why?
|
Social Isolation | 2 | 1996 | 67 | 0.200 |
Why?
|
Mutagenesis, Insertional | 1 | 2021 | 111 | 0.190 |
Why?
|
Mass Media | 1 | 2001 | 26 | 0.190 |
Why?
|
Diagnosis, Differential | 4 | 2019 | 1565 | 0.190 |
Why?
|
Chromosomes, Human, Pair 3 | 5 | 2002 | 54 | 0.190 |
Why?
|
Metabolic Clearance Rate | 4 | 2014 | 121 | 0.190 |
Why?
|
Bridged Bicyclo Compounds, Heterocyclic | 1 | 2021 | 76 | 0.190 |
Why?
|
Fatigue | 4 | 2010 | 174 | 0.190 |
Why?
|
Hematopoietic Stem Cell Mobilization | 3 | 2016 | 50 | 0.190 |
Why?
|
Homeodomain Proteins | 5 | 2014 | 536 | 0.190 |
Why?
|
Gene Deletion | 2 | 2016 | 329 | 0.190 |
Why?
|
Immunosuppressive Agents | 5 | 2015 | 977 | 0.190 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 3 | 2022 | 189 | 0.180 |
Why?
|
Codon | 2 | 2016 | 124 | 0.180 |
Why?
|
Quinolines | 2 | 2020 | 95 | 0.180 |
Why?
|
Point Mutation | 2 | 2007 | 246 | 0.180 |
Why?
|
Trisomy | 7 | 2012 | 55 | 0.180 |
Why?
|
Microarray Analysis | 3 | 2014 | 96 | 0.180 |
Why?
|
Practice Guidelines as Topic | 4 | 2021 | 1036 | 0.180 |
Why?
|
Clinical Protocols | 3 | 2018 | 156 | 0.180 |
Why?
|
NAD(P)H Dehydrogenase (Quinone) | 1 | 1999 | 8 | 0.180 |
Why?
|
Caregivers | 1 | 2001 | 151 | 0.180 |
Why?
|
Cell Cycle Proteins | 4 | 2018 | 388 | 0.180 |
Why?
|
Area Under Curve | 4 | 2014 | 334 | 0.180 |
Why?
|
Chromatography, High Pressure Liquid | 7 | 2006 | 315 | 0.180 |
Why?
|
Antibiotics, Antineoplastic | 3 | 2008 | 114 | 0.170 |
Why?
|
Leukocyte Count | 7 | 2017 | 220 | 0.170 |
Why?
|
Fetal Blood | 2 | 2017 | 90 | 0.170 |
Why?
|
Immunocompromised Host | 3 | 2016 | 140 | 0.170 |
Why?
|
Genotype | 7 | 2021 | 1851 | 0.170 |
Why?
|
Anemia | 3 | 2010 | 128 | 0.170 |
Why?
|
Interdisciplinary Communication | 1 | 2019 | 130 | 0.170 |
Why?
|
Expert Testimony | 1 | 2018 | 46 | 0.170 |
Why?
|
Core Binding Factor Alpha 2 Subunit | 6 | 2012 | 52 | 0.170 |
Why?
|
Protein Interaction Domains and Motifs | 2 | 2016 | 86 | 0.160 |
Why?
|
Drug Therapy, Combination | 4 | 2018 | 894 | 0.160 |
Why?
|
In Situ Hybridization, Fluorescence | 11 | 2015 | 348 | 0.160 |
Why?
|
Hematopoiesis | 5 | 2016 | 163 | 0.160 |
Why?
|
Esophageal Cyst | 1 | 1998 | 3 | 0.160 |
Why?
|
Mastocytosis, Systemic | 1 | 2018 | 11 | 0.160 |
Why?
|
Lymphoproliferative Disorders | 2 | 1996 | 107 | 0.160 |
Why?
|
Graft Survival | 4 | 2016 | 884 | 0.160 |
Why?
|
Drug Approval | 3 | 2018 | 62 | 0.160 |
Why?
|
Ultraviolet Rays | 4 | 2002 | 193 | 0.160 |
Why?
|
ZAP-70 Protein-Tyrosine Kinase | 3 | 2015 | 18 | 0.160 |
Why?
|
Hemorrhage | 2 | 2017 | 268 | 0.160 |
Why?
|
Patient Participation | 2 | 2022 | 216 | 0.160 |
Why?
|
DNA Methylation | 5 | 2015 | 628 | 0.160 |
Why?
|
Logistic Models | 8 | 2015 | 1186 | 0.160 |
Why?
|
Histone-Lysine N-Methyltransferase | 9 | 2012 | 154 | 0.160 |
Why?
|
Germ-Line Mutation | 2 | 2022 | 329 | 0.160 |
Why?
|
Proto-Oncogene Proteins c-myc | 3 | 2012 | 120 | 0.160 |
Why?
|
Healthcare Disparities | 1 | 2022 | 371 | 0.160 |
Why?
|
Mercaptopurine | 3 | 2014 | 53 | 0.160 |
Why?
|
Leukemic Infiltration | 2 | 2007 | 14 | 0.160 |
Why?
|
Receptors, Fc | 3 | 2017 | 33 | 0.160 |
Why?
|
Watchful Waiting | 1 | 2018 | 60 | 0.150 |
Why?
|
Atrial Fibrillation | 1 | 2021 | 288 | 0.150 |
Why?
|
Injections, Spinal | 1 | 2017 | 44 | 0.150 |
Why?
|
Chromosomes, Human, Pair 6 | 3 | 2006 | 125 | 0.150 |
Why?
|
Microsatellite Repeats | 2 | 2000 | 145 | 0.150 |
Why?
|
Life Tables | 5 | 2003 | 48 | 0.150 |
Why?
|
Chromosomes, Human, Pair 9 | 4 | 2006 | 86 | 0.150 |
Why?
|
Lymphocyte Activation | 4 | 1984 | 728 | 0.150 |
Why?
|
Preoperative Care | 1 | 2019 | 397 | 0.150 |
Why?
|
Sialic Acid Binding Ig-like Lectin 3 | 4 | 2005 | 8 | 0.150 |
Why?
|
Patient Care Team | 1 | 2019 | 280 | 0.150 |
Why?
|
Stress, Psychological | 2 | 2001 | 313 | 0.150 |
Why?
|
Neoplasm Grading | 1 | 2018 | 357 | 0.150 |
Why?
|
Pilot Projects | 9 | 2020 | 839 | 0.150 |
Why?
|
Cytomegalovirus Infections | 2 | 2009 | 144 | 0.150 |
Why?
|
Investigational New Drug Application | 1 | 2016 | 2 | 0.150 |
Why?
|
Chemoprevention | 1 | 2017 | 91 | 0.150 |
Why?
|
Amphotericin B | 3 | 1993 | 34 | 0.150 |
Why?
|
Foscarnet | 1 | 2016 | 12 | 0.150 |
Why?
|
Hematologic Diseases | 6 | 2018 | 79 | 0.150 |
Why?
|
Patient-Centered Care | 1 | 2019 | 203 | 0.150 |
Why?
|
WT1 Proteins | 3 | 2011 | 19 | 0.150 |
Why?
|
Registries | 2 | 2022 | 702 | 0.150 |
Why?
|
Alpha-Ketoglutarate-Dependent Dioxygenase FTO | 1 | 2016 | 41 | 0.140 |
Why?
|
Drug Resistance, Viral | 1 | 2016 | 51 | 0.140 |
Why?
|
Cell Dedifferentiation | 1 | 2016 | 8 | 0.140 |
Why?
|
Telomere Homeostasis | 1 | 2016 | 30 | 0.140 |
Why?
|
Superoxide Dismutase | 2 | 2016 | 177 | 0.140 |
Why?
|
Blood Donors | 1 | 2016 | 26 | 0.140 |
Why?
|
Lymphocytes | 7 | 1990 | 464 | 0.140 |
Why?
|
Predictive Value of Tests | 11 | 2014 | 1673 | 0.140 |
Why?
|
Telomerase | 1 | 2016 | 55 | 0.140 |
Why?
|
Comorbidity | 5 | 2022 | 943 | 0.140 |
Why?
|
Repressor Proteins | 3 | 2018 | 403 | 0.140 |
Why?
|
Leukemia, Prolymphocytic | 2 | 2012 | 3 | 0.140 |
Why?
|
Proto-Oncogene Proteins c-abl | 1 | 2016 | 30 | 0.140 |
Why?
|
Paramyxoviridae | 1 | 2015 | 10 | 0.140 |
Why?
|
Haploidy | 1 | 2016 | 31 | 0.140 |
Why?
|
Cell Differentiation | 6 | 2016 | 1458 | 0.140 |
Why?
|
Age Distribution | 2 | 2008 | 204 | 0.140 |
Why?
|
Ikaros Transcription Factor | 1 | 2016 | 25 | 0.140 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 3 | 2014 | 199 | 0.140 |
Why?
|
Antineoplastic Agents, Alkylating | 3 | 2004 | 138 | 0.140 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2016 | 85 | 0.140 |
Why?
|
Antibiotic Prophylaxis | 1 | 2016 | 71 | 0.140 |
Why?
|
Survivors | 2 | 2015 | 226 | 0.140 |
Why?
|
Pharmacogenomic Variants | 1 | 2016 | 41 | 0.140 |
Why?
|
Prescription Fees | 1 | 2015 | 10 | 0.130 |
Why?
|
CpG Islands | 2 | 2015 | 151 | 0.130 |
Why?
|
Chemical and Drug Induced Liver Injury | 1 | 2016 | 69 | 0.130 |
Why?
|
Microtubule-Associated Proteins | 1 | 2016 | 176 | 0.130 |
Why?
|
Gene Frequency | 5 | 2016 | 677 | 0.130 |
Why?
|
Genes, ras | 3 | 2013 | 96 | 0.130 |
Why?
|
Health Impact Assessment | 1 | 2015 | 1 | 0.130 |
Why?
|
Genetic Variation | 2 | 2019 | 1351 | 0.130 |
Why?
|
European Union | 1 | 2015 | 8 | 0.130 |
Why?
|
Community-Acquired Infections | 1 | 2015 | 63 | 0.130 |
Why?
|
Azocines | 1 | 2015 | 3 | 0.130 |
Why?
|
Physicians | 2 | 2022 | 673 | 0.130 |
Why?
|
Patents as Topic | 1 | 2015 | 12 | 0.130 |
Why?
|
Tumor Cells, Cultured | 8 | 2021 | 1041 | 0.130 |
Why?
|
Leukemia, Myelomonocytic, Acute | 1 | 1995 | 5 | 0.130 |
Why?
|
Patient Advocacy | 1 | 2015 | 49 | 0.130 |
Why?
|
Core Binding Factors | 3 | 2011 | 12 | 0.130 |
Why?
|
Immunization, Secondary | 1 | 1995 | 30 | 0.130 |
Why?
|
Sulfonic Acids | 1 | 1995 | 9 | 0.130 |
Why?
|
Immunoglobulin Heavy Chains | 5 | 2015 | 131 | 0.130 |
Why?
|
Graft Rejection | 2 | 2016 | 1065 | 0.130 |
Why?
|
Esophageal Neoplasms | 1 | 1998 | 321 | 0.130 |
Why?
|
Inhibitor of Apoptosis Proteins | 1 | 2015 | 33 | 0.130 |
Why?
|
Adaptation, Psychological | 1 | 1996 | 157 | 0.130 |
Why?
|
Chromosome Mapping | 15 | 2003 | 1074 | 0.130 |
Why?
|
Benzhydryl Compounds | 1 | 2015 | 48 | 0.130 |
Why?
|
Cost Savings | 1 | 2015 | 66 | 0.130 |
Why?
|
Hydroxamic Acids | 1 | 2014 | 49 | 0.130 |
Why?
|
Genes, BRCA2 | 1 | 2015 | 160 | 0.130 |
Why?
|
Pyridazines | 1 | 2014 | 22 | 0.130 |
Why?
|
Consensus | 3 | 2022 | 335 | 0.130 |
Why?
|
Apoptosis | 6 | 2016 | 1683 | 0.120 |
Why?
|
Transcriptional Regulator ERG | 6 | 2010 | 15 | 0.120 |
Why?
|
Genes, BRCA1 | 1 | 2015 | 192 | 0.120 |
Why?
|
Karnofsky Performance Status | 2 | 2006 | 40 | 0.120 |
Why?
|
Laboratory Chemicals | 1 | 2014 | 1 | 0.120 |
Why?
|
Paraffin Embedding | 1 | 2014 | 78 | 0.120 |
Why?
|
Social Support | 1 | 1996 | 193 | 0.120 |
Why?
|
Adenosine | 1 | 2016 | 225 | 0.120 |
Why?
|
Farnesyltranstransferase | 1 | 2013 | 6 | 0.120 |
Why?
|
Fusarium | 2 | 1993 | 4 | 0.120 |
Why?
|
DNA | 9 | 2007 | 1294 | 0.120 |
Why?
|
Cytochalasin B | 2 | 1983 | 19 | 0.120 |
Why?
|
Stem Cell Niche | 1 | 2014 | 21 | 0.120 |
Why?
|
Cell Lineage | 5 | 2002 | 273 | 0.120 |
Why?
|
Cell Survival | 3 | 2013 | 969 | 0.120 |
Why?
|
Clinical Trials, Phase III as Topic | 5 | 2022 | 172 | 0.120 |
Why?
|
Drug Synergism | 2 | 2012 | 303 | 0.120 |
Why?
|
Cell Cycle | 9 | 2010 | 502 | 0.120 |
Why?
|
Simvastatin | 1 | 2014 | 106 | 0.120 |
Why?
|
Oncogenes | 3 | 2010 | 88 | 0.120 |
Why?
|
Chromosomes, Human, Pair 17 | 4 | 2005 | 110 | 0.120 |
Why?
|
Brain Diseases | 1 | 1995 | 180 | 0.120 |
Why?
|
Imidazoles | 1 | 2014 | 162 | 0.120 |
Why?
|
Nausea | 3 | 2010 | 175 | 0.120 |
Why?
|
Topoisomerase II Inhibitors | 3 | 2000 | 27 | 0.120 |
Why?
|
Blood Component Transfusion | 1 | 1993 | 13 | 0.120 |
Why?
|
Radiation Tolerance | 1 | 2014 | 168 | 0.120 |
Why?
|
Glucocorticoids | 1 | 2015 | 352 | 0.110 |
Why?
|
Body Surface Area | 2 | 2015 | 36 | 0.110 |
Why?
|
Iron | 2 | 2001 | 164 | 0.110 |
Why?
|
Drug Resistance | 7 | 2007 | 256 | 0.110 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2013 | 101 | 0.110 |
Why?
|
Antigens, Differentiation, B-Lymphocyte | 1 | 2012 | 19 | 0.110 |
Why?
|
Amsacrine | 1 | 1992 | 3 | 0.110 |
Why?
|
Peripheral Nervous System | 1 | 2012 | 21 | 0.110 |
Why?
|
Sex Factors | 5 | 2008 | 1054 | 0.110 |
Why?
|
DNA Topoisomerases, Type II | 2 | 2003 | 20 | 0.110 |
Why?
|
Dioxolanes | 2 | 2003 | 8 | 0.110 |
Why?
|
Hypohidrosis | 1 | 2012 | 2 | 0.110 |
Why?
|
Drug Interactions | 2 | 2012 | 248 | 0.110 |
Why?
|
Alopecia Areata | 1 | 2012 | 4 | 0.110 |
Why?
|
Obesity | 2 | 2019 | 963 | 0.110 |
Why?
|
Haemophilus influenzae | 1 | 1992 | 13 | 0.110 |
Why?
|
Hypopigmentation | 1 | 2012 | 4 | 0.110 |
Why?
|
Blood Component Removal | 2 | 2008 | 24 | 0.110 |
Why?
|
Boronic Acids | 1 | 2012 | 55 | 0.110 |
Why?
|
Base Sequence | 9 | 2012 | 2330 | 0.110 |
Why?
|
Sequence Analysis, DNA | 2 | 2015 | 853 | 0.110 |
Why?
|
Listeriosis | 1 | 1993 | 84 | 0.110 |
Why?
|
Hypertension | 1 | 2021 | 1141 | 0.110 |
Why?
|
Benzimidazoles | 1 | 2013 | 140 | 0.110 |
Why?
|
DNA, Bacterial | 2 | 1992 | 236 | 0.110 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 2 | 2022 | 154 | 0.110 |
Why?
|
Lung Diseases, Fungal | 2 | 1992 | 17 | 0.110 |
Why?
|
Signal Transduction | 5 | 2018 | 3241 | 0.110 |
Why?
|
Hypotension | 2 | 2009 | 70 | 0.110 |
Why?
|
Chromosomes, Human, Pair 22 | 3 | 2004 | 43 | 0.110 |
Why?
|
Monitoring, Physiologic | 3 | 2020 | 268 | 0.110 |
Why?
|
Histocompatibility Antigens Class II | 1 | 2012 | 158 | 0.100 |
Why?
|
DNA Repair | 2 | 2013 | 356 | 0.100 |
Why?
|
Mastectomy | 1 | 2014 | 243 | 0.100 |
Why?
|
Chlorambucil | 4 | 2012 | 23 | 0.100 |
Why?
|
Statistics, Nonparametric | 6 | 2008 | 307 | 0.100 |
Why?
|
North America | 2 | 2010 | 180 | 0.100 |
Why?
|
Cell Line, Tumor | 5 | 2018 | 2426 | 0.100 |
Why?
|
Receptor Protein-Tyrosine Kinases | 2 | 2004 | 153 | 0.100 |
Why?
|
Evaluation Studies as Topic | 2 | 2005 | 274 | 0.100 |
Why?
|
Bone Marrow Neoplasms | 1 | 2011 | 17 | 0.100 |
Why?
|
Mice | 9 | 2023 | 11352 | 0.100 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2015 | 456 | 0.100 |
Why?
|
Alkylating Agents | 2 | 2009 | 32 | 0.100 |
Why?
|
Methyltransferases | 5 | 2018 | 182 | 0.100 |
Why?
|
Infant | 6 | 2018 | 3046 | 0.100 |
Why?
|
History, 20th Century | 2 | 2018 | 312 | 0.100 |
Why?
|
Drug Tolerance | 2 | 2010 | 63 | 0.100 |
Why?
|
Child Development | 2 | 1991 | 163 | 0.100 |
Why?
|
Clinical Trials, Phase I as Topic | 3 | 2007 | 155 | 0.100 |
Why?
|
Leukocytosis | 2 | 2007 | 16 | 0.100 |
Why?
|
Genetic Markers | 7 | 2008 | 476 | 0.100 |
Why?
|
Chromosomes, Human, Pair 12 | 4 | 1998 | 65 | 0.100 |
Why?
|
Adenocarcinoma | 2 | 1998 | 1169 | 0.100 |
Why?
|
Hepatic Veno-Occlusive Disease | 1 | 2010 | 19 | 0.100 |
Why?
|
Antigen-Antibody Complex | 1 | 1991 | 87 | 0.100 |
Why?
|
Case-Control Studies | 5 | 2021 | 1805 | 0.100 |
Why?
|
Electroencephalography | 1 | 1995 | 709 | 0.090 |
Why?
|
Genes, Immunoglobulin Heavy Chain | 2 | 2011 | 9 | 0.090 |
Why?
|
Aging | 2 | 2012 | 691 | 0.090 |
Why?
|
Proto-Oncogene Proteins c-cbl | 1 | 2010 | 36 | 0.090 |
Why?
|
RNA-Binding Proteins | 1 | 2012 | 246 | 0.090 |
Why?
|
Chromosomes, Human, 16-18 | 3 | 1984 | 26 | 0.090 |
Why?
|
Epigenomics | 1 | 2011 | 100 | 0.090 |
Why?
|
Granulocytes | 2 | 1993 | 37 | 0.090 |
Why?
|
Filgrastim | 3 | 2014 | 56 | 0.090 |
Why?
|
Social Behavior | 2 | 1991 | 294 | 0.090 |
Why?
|
Receptors, Antigen, T-Cell | 3 | 2013 | 372 | 0.090 |
Why?
|
Cross-Over Studies | 5 | 2017 | 399 | 0.090 |
Why?
|
CD52 Antigen | 1 | 2009 | 3 | 0.090 |
Why?
|
DNA Probes | 2 | 2008 | 77 | 0.090 |
Why?
|
Activities of Daily Living | 2 | 2022 | 204 | 0.090 |
Why?
|
Immunologic Factors | 3 | 2005 | 170 | 0.090 |
Why?
|
Psychology, Adolescent | 1 | 1989 | 29 | 0.090 |
Why?
|
Transplantation Chimera | 1 | 2009 | 80 | 0.090 |
Why?
|
Membrane Proteins | 1 | 2016 | 1196 | 0.090 |
Why?
|
Chromosomes, Human, Pair 13 | 2 | 2002 | 51 | 0.090 |
Why?
|
Prodrugs | 1 | 2009 | 46 | 0.090 |
Why?
|
Glutathione | 1 | 2009 | 104 | 0.090 |
Why?
|
Tissue Donors | 1 | 2012 | 463 | 0.080 |
Why?
|
Carbolines | 1 | 1988 | 8 | 0.080 |
Why?
|
Lepidoptera | 1 | 1988 | 14 | 0.080 |
Why?
|
Idarubicin | 2 | 2023 | 8 | 0.080 |
Why?
|
Patient Reported Outcome Measures | 2 | 2022 | 166 | 0.080 |
Why?
|
Alkaloids | 1 | 1988 | 45 | 0.080 |
Why?
|
International Cooperation | 3 | 2016 | 127 | 0.080 |
Why?
|
Anti-Infective Agents | 1 | 2009 | 89 | 0.080 |
Why?
|
Platelet Count | 4 | 2017 | 92 | 0.080 |
Why?
|
Depsipeptides | 1 | 2008 | 29 | 0.080 |
Why?
|
Dioxygenases | 3 | 2016 | 74 | 0.080 |
Why?
|
Skin | 2 | 2007 | 554 | 0.080 |
Why?
|
Epigenesis, Genetic | 4 | 2016 | 479 | 0.080 |
Why?
|
Cause of Death | 2 | 2018 | 277 | 0.080 |
Why?
|
Splenomegaly | 2 | 2006 | 27 | 0.080 |
Why?
|
Models, Biological | 2 | 2014 | 1749 | 0.080 |
Why?
|
Genes, abl | 2 | 2010 | 12 | 0.080 |
Why?
|
United States Food and Drug Administration | 3 | 2018 | 127 | 0.080 |
Why?
|
Chromosomes, Human | 4 | 2003 | 66 | 0.080 |
Why?
|
Blood Platelets | 2 | 2017 | 149 | 0.080 |
Why?
|
Glycoproteins | 1 | 2009 | 234 | 0.080 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 1 | 2008 | 30 | 0.080 |
Why?
|
Ovarian Neoplasms | 1 | 1995 | 744 | 0.080 |
Why?
|
Severity of Illness Index | 2 | 2005 | 1801 | 0.080 |
Why?
|
Emotions | 2 | 1989 | 341 | 0.080 |
Why?
|
Genital Neoplasms, Male | 1 | 1988 | 11 | 0.080 |
Why?
|
Chimerism | 2 | 2020 | 37 | 0.080 |
Why?
|
Scrotum | 1 | 1988 | 17 | 0.080 |
Why?
|
Quinoxalines | 1 | 2008 | 50 | 0.080 |
Why?
|
C-Reactive Protein | 1 | 2008 | 190 | 0.080 |
Why?
|
Acute Kidney Injury | 1 | 2011 | 295 | 0.080 |
Why?
|
Hemangioma | 1 | 1988 | 60 | 0.080 |
Why?
|
Uveitis | 1 | 2007 | 29 | 0.080 |
Why?
|
Up-Regulation | 4 | 2014 | 712 | 0.080 |
Why?
|
Leiomyosarcoma | 1 | 1988 | 40 | 0.080 |
Why?
|
Clinical Decision-Making | 2 | 2020 | 257 | 0.080 |
Why?
|
Demography | 1 | 2008 | 177 | 0.080 |
Why?
|
Diarrhea | 3 | 2012 | 182 | 0.080 |
Why?
|
Medication Adherence | 1 | 2009 | 129 | 0.080 |
Why?
|
Interleukin-6 | 1 | 2008 | 256 | 0.080 |
Why?
|
Pericardial Effusion | 1 | 2007 | 19 | 0.080 |
Why?
|
Transplantation, Haploidentical | 2 | 2017 | 27 | 0.070 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2009 | 276 | 0.070 |
Why?
|
Rubber | 2 | 1996 | 6 | 0.070 |
Why?
|
Butadienes | 2 | 1996 | 33 | 0.070 |
Why?
|
DNA Replication | 3 | 1989 | 164 | 0.070 |
Why?
|
Genomics | 2 | 2022 | 720 | 0.070 |
Why?
|
Retreatment | 2 | 2017 | 107 | 0.070 |
Why?
|
Alleles | 4 | 2011 | 1128 | 0.070 |
Why?
|
Blotting, Southern | 3 | 2003 | 129 | 0.070 |
Why?
|
Liver | 3 | 2019 | 1230 | 0.070 |
Why?
|
Methylation | 2 | 2018 | 251 | 0.070 |
Why?
|
Chromosome Breakage | 2 | 2003 | 17 | 0.070 |
Why?
|
Body Weight | 1 | 2008 | 459 | 0.070 |
Why?
|
Anthracyclines | 2 | 2019 | 37 | 0.070 |
Why?
|
Pneumonia | 1 | 1988 | 179 | 0.070 |
Why?
|
Blood Cell Count | 5 | 2007 | 79 | 0.070 |
Why?
|
Mediastinal Neoplasms | 2 | 1998 | 46 | 0.070 |
Why?
|
Occupational Diseases | 2 | 1996 | 55 | 0.070 |
Why?
|
Prevalence | 2 | 2022 | 1239 | 0.070 |
Why?
|
Graft vs Leukemia Effect | 1 | 2006 | 11 | 0.070 |
Why?
|
RNA, Messenger | 6 | 2010 | 1981 | 0.070 |
Why?
|
Aminopterin | 1 | 2005 | 5 | 0.070 |
Why?
|
Intention to Treat Analysis | 2 | 2017 | 72 | 0.070 |
Why?
|
Ganciclovir | 1 | 2006 | 49 | 0.070 |
Why?
|
Folic Acid Antagonists | 1 | 2005 | 19 | 0.070 |
Why?
|
Health Planning Guidelines | 2 | 2019 | 24 | 0.070 |
Why?
|
Genetic Testing | 2 | 2022 | 535 | 0.070 |
Why?
|
Patient Compliance | 2 | 2005 | 227 | 0.070 |
Why?
|
Placebos | 2 | 2012 | 218 | 0.070 |
Why?
|
Blood Transfusion | 1 | 2006 | 157 | 0.070 |
Why?
|
Chromosomes, Artificial, Yeast | 3 | 2000 | 37 | 0.070 |
Why?
|
Single-Blind Method | 1 | 2005 | 153 | 0.070 |
Why?
|
Respiratory Insufficiency | 1 | 2007 | 150 | 0.070 |
Why?
|
Xylose | 1 | 1984 | 23 | 0.060 |
Why?
|
Quantitative Trait Loci | 1 | 2009 | 576 | 0.060 |
Why?
|
Hyperphagia | 1 | 1985 | 35 | 0.060 |
Why?
|
Stomatitis | 2 | 2000 | 30 | 0.060 |
Why?
|
Chromosome Banding | 7 | 2000 | 74 | 0.060 |
Why?
|
Chromosomes, Human, Pair 15 | 2 | 2002 | 63 | 0.060 |
Why?
|
Chromosomes, Human, Pair 1 | 2 | 2002 | 100 | 0.060 |
Why?
|
DNA Primers | 3 | 2006 | 543 | 0.060 |
Why?
|
Chromosomes, Human, 13-15 | 1 | 1984 | 32 | 0.060 |
Why?
|
Forecasting | 2 | 2004 | 304 | 0.060 |
Why?
|
Chi-Square Distribution | 2 | 2014 | 364 | 0.060 |
Why?
|
Surveys and Questionnaires | 3 | 2019 | 2501 | 0.060 |
Why?
|
Kinetics | 4 | 2002 | 1513 | 0.060 |
Why?
|
Molecular Sequence Data | 6 | 2012 | 3030 | 0.060 |
Why?
|
Cannabis | 1 | 1984 | 34 | 0.060 |
Why?
|
Cholesterol | 4 | 2016 | 356 | 0.060 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 2 | 2014 | 70 | 0.060 |
Why?
|
Cell Separation | 3 | 1994 | 196 | 0.060 |
Why?
|
Photochemistry | 2 | 2002 | 38 | 0.060 |
Why?
|
Oncogene Proteins | 1 | 2004 | 59 | 0.060 |
Why?
|
Drug Discovery | 2 | 2018 | 103 | 0.060 |
Why?
|
Double-Blind Method | 3 | 2012 | 1823 | 0.060 |
Why?
|
Lactation | 1 | 2023 | 53 | 0.060 |
Why?
|
Income | 1 | 2023 | 75 | 0.060 |
Why?
|
Tumor Lysis Syndrome | 1 | 2003 | 9 | 0.060 |
Why?
|
Urate Oxidase | 1 | 2003 | 11 | 0.060 |
Why?
|
Bone Marrow Examination | 1 | 2003 | 48 | 0.060 |
Why?
|
Biomarkers | 2 | 2015 | 1718 | 0.060 |
Why?
|
Social Determinants of Health | 1 | 2024 | 78 | 0.060 |
Why?
|
Genome-Wide Association Study | 3 | 2021 | 1621 | 0.060 |
Why?
|
Genes, p53 | 2 | 2007 | 109 | 0.060 |
Why?
|
Palliative Care | 2 | 2019 | 257 | 0.060 |
Why?
|
Myeloid Ecotropic Viral Integration Site 1 Protein | 2 | 2012 | 20 | 0.060 |
Why?
|
Genes | 3 | 1990 | 305 | 0.060 |
Why?
|
Cytological Techniques | 1 | 2002 | 30 | 0.060 |
Why?
|
Hyperuricemia | 1 | 2003 | 27 | 0.060 |
Why?
|
Breast Feeding | 1 | 2023 | 91 | 0.060 |
Why?
|
Patients | 1 | 2023 | 100 | 0.060 |
Why?
|
RNA, Small Interfering | 2 | 2018 | 547 | 0.060 |
Why?
|
Central Nervous System Diseases | 1 | 2003 | 52 | 0.060 |
Why?
|
Feeding and Eating Disorders | 1 | 1985 | 173 | 0.060 |
Why?
|
Amyloidosis | 1 | 2004 | 115 | 0.060 |
Why?
|
Cytokines | 2 | 2018 | 776 | 0.060 |
Why?
|
Diet, High-Fat | 1 | 2023 | 114 | 0.050 |
Why?
|
Colony-Stimulating Factors | 3 | 1987 | 14 | 0.050 |
Why?
|
Reproducibility of Results | 2 | 2021 | 2705 | 0.050 |
Why?
|
Protein Binding | 2 | 2018 | 1456 | 0.050 |
Why?
|
Interferon-gamma | 1 | 2004 | 444 | 0.050 |
Why?
|
World Health Organization | 1 | 2022 | 103 | 0.050 |
Why?
|
Cetrimonium Compounds | 1 | 2002 | 2 | 0.050 |
Why?
|
Deoxyribonuclease I | 1 | 2002 | 28 | 0.050 |
Why?
|
Fever | 2 | 1996 | 125 | 0.050 |
Why?
|
Prednisone | 5 | 1996 | 258 | 0.050 |
Why?
|
Cell Division | 5 | 1992 | 696 | 0.050 |
Why?
|
Borohydrides | 1 | 2002 | 7 | 0.050 |
Why?
|
Plasmids | 2 | 1993 | 287 | 0.050 |
Why?
|
Affect | 1 | 1985 | 386 | 0.050 |
Why?
|
Family | 3 | 2012 | 311 | 0.050 |
Why?
|
Aldehyde Reductase | 1 | 2021 | 9 | 0.050 |
Why?
|
Myeloablative Agonists | 2 | 2014 | 34 | 0.050 |
Why?
|
Preleukemia | 3 | 1986 | 10 | 0.050 |
Why?
|
Voluntary Health Agencies | 1 | 2021 | 5 | 0.050 |
Why?
|
Breast Neoplasms | 1 | 2015 | 2903 | 0.050 |
Why?
|
Stem Cells | 1 | 1984 | 351 | 0.050 |
Why?
|
Echocardiography | 1 | 2007 | 911 | 0.050 |
Why?
|
Biological Specimen Banks | 1 | 2022 | 65 | 0.050 |
Why?
|
Skin Diseases, Infectious | 1 | 2001 | 13 | 0.050 |
Why?
|
Toxicology | 1 | 2021 | 16 | 0.050 |
Why?
|
Health Care Costs | 1 | 2023 | 238 | 0.050 |
Why?
|
International Agencies | 2 | 2012 | 34 | 0.050 |
Why?
|
Immunoblastic Lymphadenopathy | 2 | 1996 | 5 | 0.050 |
Why?
|
Alcohol Drinking | 1 | 1984 | 267 | 0.050 |
Why?
|
Tacrolimus | 2 | 2015 | 373 | 0.050 |
Why?
|
Hydrocarbons, Chlorinated | 1 | 2001 | 4 | 0.050 |
Why?
|
Silicates | 1 | 2001 | 8 | 0.050 |
Why?
|
Analysis of Variance | 4 | 2008 | 912 | 0.050 |
Why?
|
Physical Chromosome Mapping | 1 | 2001 | 27 | 0.050 |
Why?
|
Television | 1 | 2001 | 29 | 0.050 |
Why?
|
Cell Line | 4 | 2016 | 2468 | 0.050 |
Why?
|
Length of Stay | 2 | 2008 | 702 | 0.050 |
Why?
|
Creatinine | 1 | 2002 | 338 | 0.050 |
Why?
|
Sepsis | 1 | 1984 | 306 | 0.050 |
Why?
|
Mood Disorders | 1 | 2001 | 81 | 0.050 |
Why?
|
Transcription, Genetic | 6 | 2006 | 1135 | 0.050 |
Why?
|
Cell Proliferation | 2 | 2016 | 1578 | 0.050 |
Why?
|
Survival | 1 | 2000 | 21 | 0.050 |
Why?
|
Illinois | 2 | 2012 | 462 | 0.050 |
Why?
|
Rosette Formation | 3 | 1984 | 34 | 0.050 |
Why?
|
Transcriptome | 2 | 2016 | 580 | 0.050 |
Why?
|
Expressed Sequence Tags | 3 | 2006 | 35 | 0.050 |
Why?
|
Hydrazines | 1 | 2020 | 30 | 0.050 |
Why?
|
Consensus Development Conferences as Topic | 1 | 2020 | 28 | 0.050 |
Why?
|
Tumor Microenvironment | 1 | 2023 | 418 | 0.050 |
Why?
|
Megakaryocytes | 2 | 1998 | 36 | 0.050 |
Why?
|
Neurotoxicity Syndromes | 1 | 2000 | 28 | 0.050 |
Why?
|
Mouth Mucosa | 1 | 2000 | 67 | 0.050 |
Why?
|
Gene Expression Regulation | 2 | 2006 | 1920 | 0.040 |
Why?
|
Life Expectancy | 1 | 2020 | 86 | 0.040 |
Why?
|
Infant, Newborn | 2 | 2018 | 2379 | 0.040 |
Why?
|
Heart Failure | 4 | 2009 | 1204 | 0.040 |
Why?
|
Triazoles | 1 | 2020 | 96 | 0.040 |
Why?
|
Patient Selection | 2 | 2019 | 685 | 0.040 |
Why?
|
Nitriles | 1 | 2020 | 149 | 0.040 |
Why?
|
Immunoglobulin Variable Region | 2 | 2012 | 109 | 0.040 |
Why?
|
Focal Infection, Dental | 1 | 1999 | 3 | 0.040 |
Why?
|
Dental Care for Chronically Ill | 1 | 1999 | 4 | 0.040 |
Why?
|
RNA | 3 | 2016 | 560 | 0.040 |
Why?
|
Health Plan Implementation | 1 | 2019 | 56 | 0.040 |
Why?
|
Leukocytes, Mononuclear | 2 | 2006 | 196 | 0.040 |
Why?
|
Historically Controlled Study | 1 | 2019 | 5 | 0.040 |
Why?
|
Gastrointestinal Agents | 1 | 2001 | 161 | 0.040 |
Why?
|
Standard of Care | 1 | 2019 | 79 | 0.040 |
Why?
|
Mice, Inbred C57BL | 2 | 2016 | 3092 | 0.040 |
Why?
|
Stereoisomerism | 3 | 2008 | 102 | 0.040 |
Why?
|
Proteins | 2 | 2003 | 777 | 0.040 |
Why?
|
Heterogeneous-Nuclear Ribonucleoprotein K | 1 | 2018 | 3 | 0.040 |
Why?
|
Cluster Analysis | 2 | 2012 | 369 | 0.040 |
Why?
|
Cyclin-Dependent Kinase 9 | 1 | 2018 | 6 | 0.040 |
Why?
|
GATA1 Transcription Factor | 1 | 2018 | 18 | 0.040 |
Why?
|
Mental Health | 1 | 2019 | 162 | 0.040 |
Why?
|
Preoperative Period | 1 | 2018 | 91 | 0.040 |
Why?
|
Histiocytes | 1 | 1998 | 22 | 0.040 |
Why?
|
Chromatin Assembly and Disassembly | 1 | 2018 | 69 | 0.040 |
Why?
|
Lovastatin | 2 | 1991 | 29 | 0.040 |
Why?
|
Harringtonines | 2 | 2008 | 4 | 0.040 |
Why?
|
Lymphocyte Depletion | 1 | 2017 | 97 | 0.040 |
Why?
|
Receptors, Thrombopoietin | 1 | 2017 | 4 | 0.040 |
Why?
|
Sulfuric Acids | 1 | 1997 | 6 | 0.040 |
Why?
|
Respiratory Tract Neoplasms | 1 | 1997 | 2 | 0.040 |
Why?
|
Pedigree | 2 | 2016 | 966 | 0.040 |
Why?
|
Genes, myc | 2 | 1994 | 39 | 0.040 |
Why?
|
Anemia, Aplastic | 2 | 2012 | 30 | 0.040 |
Why?
|
Interferon Type I | 2 | 2006 | 175 | 0.040 |
Why?
|
Nervous System Diseases | 1 | 2018 | 151 | 0.040 |
Why?
|
Hematopoietic Cell Growth Factors | 1 | 1997 | 11 | 0.040 |
Why?
|
Chromosomes, Human, Pair 2 | 2 | 2004 | 85 | 0.040 |
Why?
|
Retinoic Acid Receptor alpha | 1 | 2016 | 18 | 0.040 |
Why?
|
History, 21st Century | 1 | 2018 | 175 | 0.040 |
Why?
|
Postoperative Complications | 1 | 2007 | 2207 | 0.040 |
Why?
|
Suppressor of Cytokine Signaling Proteins | 1 | 2016 | 20 | 0.040 |
Why?
|
Styrenes | 1 | 1996 | 7 | 0.040 |
Why?
|
Benzene | 1 | 1996 | 8 | 0.040 |
Why?
|
Body Mass Index | 2 | 2015 | 770 | 0.040 |
Why?
|
Sequence Deletion | 1 | 1997 | 205 | 0.040 |
Why?
|
Chromosomes, Human, 6-12 and X | 3 | 1986 | 23 | 0.040 |
Why?
|
Lymphocyte Subsets | 2 | 2013 | 64 | 0.040 |
Why?
|
Glucosephosphate Dehydrogenase | 1 | 2016 | 18 | 0.040 |
Why?
|
Pentose Phosphate Pathway | 1 | 2016 | 11 | 0.040 |
Why?
|
Mitomycin | 3 | 2003 | 29 | 0.040 |
Why?
|
Chromosomes, Human, 4-5 | 2 | 1986 | 10 | 0.040 |
Why?
|
Mental Disorders | 1 | 2000 | 371 | 0.040 |
Why?
|
Models, Econometric | 1 | 2016 | 14 | 0.040 |
Why?
|
Pregnancy | 1 | 2023 | 2894 | 0.040 |
Why?
|
Multiplex Polymerase Chain Reaction | 1 | 2015 | 33 | 0.030 |
Why?
|
Histocompatibility | 1 | 2016 | 71 | 0.030 |
Why?
|
Somatoform Disorders | 1 | 1996 | 29 | 0.030 |
Why?
|
Digestive System Diseases | 1 | 1996 | 18 | 0.030 |
Why?
|
Personality Assessment | 1 | 1996 | 98 | 0.030 |
Why?
|
Markov Chains | 1 | 2016 | 125 | 0.030 |
Why?
|
Morbidity | 1 | 1996 | 148 | 0.030 |
Why?
|
Chromosomes, Human, Pair 14 | 2 | 1998 | 49 | 0.030 |
Why?
|
Aziridines | 2 | 2005 | 9 | 0.030 |
Why?
|
Exome | 1 | 2016 | 127 | 0.030 |
Why?
|
Thioguanine | 1 | 1995 | 17 | 0.030 |
Why?
|
Quality-Adjusted Life Years | 1 | 2016 | 138 | 0.030 |
Why?
|
Benzoquinones | 2 | 2005 | 27 | 0.030 |
Why?
|
Pharmacogenomic Testing | 1 | 2016 | 97 | 0.030 |
Why?
|
Cranial Irradiation | 1 | 1995 | 36 | 0.030 |
Why?
|
Chromatin | 1 | 2018 | 380 | 0.030 |
Why?
|
Leukemia, Erythroblastic, Acute | 2 | 1992 | 29 | 0.030 |
Why?
|
Ticlopidine | 1 | 1995 | 25 | 0.030 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2014 | 24 | 0.030 |
Why?
|
Endodermal Sinus Tumor | 1 | 1994 | 3 | 0.030 |
Why?
|
Leukopenia | 1 | 1995 | 65 | 0.030 |
Why?
|
Mortality | 1 | 2016 | 149 | 0.030 |
Why?
|
Coma | 1 | 1995 | 44 | 0.030 |
Why?
|
Genes, fms | 1 | 1994 | 2 | 0.030 |
Why?
|
Nanoparticles | 1 | 2016 | 157 | 0.030 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2014 | 74 | 0.030 |
Why?
|
Diphtheria Toxin | 1 | 1994 | 20 | 0.030 |
Why?
|
Phosphorylation | 1 | 2017 | 1106 | 0.030 |
Why?
|
Longitudinal Studies | 1 | 2018 | 1019 | 0.030 |
Why?
|
Bacterial Proteins | 1 | 2000 | 864 | 0.030 |
Why?
|
Oligonucleotides, Antisense | 2 | 2005 | 69 | 0.030 |
Why?
|
Transplant Recipients | 1 | 2015 | 122 | 0.030 |
Why?
|
Tissue Fixation | 1 | 2014 | 40 | 0.030 |
Why?
|
Research Design | 1 | 2018 | 594 | 0.030 |
Why?
|
Formaldehyde | 1 | 2014 | 52 | 0.030 |
Why?
|
Psychometrics | 1 | 1996 | 327 | 0.030 |
Why?
|
Warfarin | 1 | 1995 | 103 | 0.030 |
Why?
|
Spheroids, Cellular | 1 | 2014 | 31 | 0.030 |
Why?
|
Catalytic Domain | 1 | 2014 | 156 | 0.030 |
Why?
|
Mitogens | 2 | 1984 | 64 | 0.030 |
Why?
|
B-Lymphocytes | 5 | 1999 | 724 | 0.030 |
Why?
|
Flow Cytometry | 3 | 2001 | 679 | 0.030 |
Why?
|
MCF-7 Cells | 1 | 2014 | 106 | 0.030 |
Why?
|
HEK293 Cells | 1 | 2016 | 615 | 0.030 |
Why?
|
Drug Substitution | 1 | 2014 | 25 | 0.030 |
Why?
|
Lung | 1 | 2000 | 1170 | 0.030 |
Why?
|
Monosomy | 2 | 1995 | 12 | 0.030 |
Why?
|
MDS1 and EVI1 Complex Locus Protein | 1 | 2013 | 6 | 0.030 |
Why?
|
Emergency Medical Technicians | 1 | 1993 | 14 | 0.030 |
Why?
|
Thoracostomy | 1 | 1993 | 10 | 0.030 |
Why?
|
Liposarcoma | 1 | 1993 | 10 | 0.030 |
Why?
|
Cross-Sectional Studies | 2 | 2012 | 1621 | 0.030 |
Why?
|
Intubation | 1 | 1993 | 21 | 0.030 |
Why?
|
Gene Amplification | 2 | 2007 | 131 | 0.030 |
Why?
|
Gene Library | 2 | 2006 | 130 | 0.030 |
Why?
|
Cost-Benefit Analysis | 1 | 2016 | 454 | 0.030 |
Why?
|
Ribonucleoproteins | 1 | 1993 | 38 | 0.030 |
Why?
|
Immunoglobulin Isotypes | 1 | 2013 | 32 | 0.030 |
Why?
|
Pneumococcal Vaccines | 1 | 2013 | 28 | 0.030 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2014 | 292 | 0.030 |
Why?
|
Cells, Cultured | 4 | 1991 | 2818 | 0.030 |
Why?
|
Lymphocyte Count | 1 | 2013 | 94 | 0.030 |
Why?
|
Dogs | 1 | 2014 | 685 | 0.030 |
Why?
|
Genes, Neoplasm | 1 | 2012 | 37 | 0.030 |
Why?
|
Data Interpretation, Statistical | 1 | 2014 | 297 | 0.030 |
Why?
|
Antigens, Differentiation | 2 | 1990 | 141 | 0.030 |
Why?
|
Monoterpenes | 1 | 1992 | 5 | 0.030 |
Why?
|
Terpenes | 1 | 1992 | 17 | 0.030 |
Why?
|
Drug Evaluation | 2 | 2008 | 141 | 0.030 |
Why?
|
Leukemia, Hairy Cell | 1 | 1993 | 186 | 0.030 |
Why?
|
Thalidomide | 1 | 2012 | 54 | 0.030 |
Why?
|
Free Radicals | 1 | 1992 | 73 | 0.030 |
Why?
|
Cloning, Molecular | 3 | 2002 | 646 | 0.030 |
Why?
|
F-Box Proteins | 1 | 2012 | 8 | 0.030 |
Why?
|
Virus Diseases | 1 | 2013 | 97 | 0.030 |
Why?
|
Aspergillosis | 1 | 1992 | 41 | 0.030 |
Why?
|
Opportunistic Infections | 1 | 1992 | 59 | 0.030 |
Why?
|
Molecular Dynamics Simulation | 1 | 2014 | 245 | 0.030 |
Why?
|
Chromosomes, Human, 21-22 and Y | 2 | 1982 | 14 | 0.030 |
Why?
|
Ataxia Telangiectasia Mutated Proteins | 1 | 2012 | 52 | 0.030 |
Why?
|
Biopsy | 2 | 1993 | 1163 | 0.030 |
Why?
|
Depression | 1 | 1996 | 473 | 0.030 |
Why?
|
RUNX1 Translocation Partner 1 Protein | 2 | 2002 | 8 | 0.030 |
Why?
|
Ubiquitin Thiolesterase | 1 | 2012 | 63 | 0.030 |
Why?
|
Singapore | 1 | 2011 | 16 | 0.030 |
Why?
|
Adult Stem Cells | 1 | 2011 | 30 | 0.030 |
Why?
|
Blood Glucose | 1 | 2016 | 873 | 0.030 |
Why?
|
Anticoagulants | 1 | 1995 | 408 | 0.030 |
Why?
|
Brazil | 1 | 2011 | 69 | 0.030 |
Why?
|
Interleukin-1 | 1 | 1991 | 71 | 0.030 |
Why?
|
Environmental Exposure | 1 | 2014 | 296 | 0.030 |
Why?
|
Australia | 1 | 2011 | 99 | 0.030 |
Why?
|
Regulatory Sequences, Nucleic Acid | 1 | 2012 | 148 | 0.030 |
Why?
|
London | 1 | 2011 | 16 | 0.020 |
Why?
|
Complement C1q | 1 | 1991 | 10 | 0.020 |
Why?
|
Neoadjuvant Therapy | 1 | 2013 | 318 | 0.020 |
Why?
|
Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 1 | 1990 | 17 | 0.020 |
Why?
|
Data Collection | 1 | 2012 | 372 | 0.020 |
Why?
|
Brain Neoplasms | 1 | 1997 | 763 | 0.020 |
Why?
|
Lymphocytosis | 1 | 1990 | 10 | 0.020 |
Why?
|
Heterozygote | 1 | 1992 | 365 | 0.020 |
Why?
|
Janus Kinase 2 | 1 | 2011 | 57 | 0.020 |
Why?
|
Genetic Association Studies | 1 | 2012 | 294 | 0.020 |
Why?
|
Blotting, Northern | 3 | 1998 | 256 | 0.020 |
Why?
|
Mice, Knockout | 1 | 2015 | 1924 | 0.020 |
Why?
|
Adaptor Proteins, Signal Transducing | 2 | 2004 | 302 | 0.020 |
Why?
|
STAT5 Transcription Factor | 1 | 2010 | 42 | 0.020 |
Why?
|
Secondary Prevention | 1 | 2011 | 162 | 0.020 |
Why?
|
Hypothyroidism | 1 | 2012 | 232 | 0.020 |
Why?
|
Cytotoxicity, Immunologic | 1 | 1991 | 213 | 0.020 |
Why?
|
Autoimmune Diseases | 1 | 2012 | 241 | 0.020 |
Why?
|
Blotting, Western | 2 | 2004 | 782 | 0.020 |
Why?
|
Drug Combinations | 1 | 2010 | 224 | 0.020 |
Why?
|
Pleural Effusion | 1 | 2010 | 45 | 0.020 |
Why?
|
Computer Simulation | 1 | 2014 | 1078 | 0.020 |
Why?
|
Semantic Differential | 1 | 1989 | 1 | 0.020 |
Why?
|
Glomerular Filtration Rate | 1 | 2011 | 384 | 0.020 |
Why?
|
src-Family Kinases | 1 | 2010 | 74 | 0.020 |
Why?
|
Psychology, Child | 1 | 1989 | 12 | 0.020 |
Why?
|
Interferons | 1 | 2010 | 133 | 0.020 |
Why?
|
GTP-Binding Proteins | 1 | 2010 | 146 | 0.020 |
Why?
|
Exons | 1 | 2011 | 450 | 0.020 |
Why?
|
Interpersonal Relations | 1 | 1991 | 170 | 0.020 |
Why?
|
Muscle Cramp | 1 | 2009 | 5 | 0.020 |
Why?
|
Zinc Fingers | 2 | 2003 | 56 | 0.020 |
Why?
|
Hydrochloric Acid | 1 | 2009 | 11 | 0.020 |
Why?
|
CD3 Complex | 1 | 2009 | 135 | 0.020 |
Why?
|
Drug Eruptions | 1 | 1989 | 35 | 0.020 |
Why?
|
Sister Chromatid Exchange | 1 | 1989 | 12 | 0.020 |
Why?
|
Ideal Body Weight | 1 | 2009 | 2 | 0.020 |
Why?
|
Edema | 1 | 2009 | 71 | 0.020 |
Why?
|
Liposomes | 1 | 2009 | 91 | 0.020 |
Why?
|
Mitomycins | 2 | 1989 | 13 | 0.020 |
Why?
|
Injections | 1 | 2009 | 109 | 0.020 |
Why?
|
Singlet Oxygen | 1 | 1988 | 7 | 0.020 |
Why?
|
O(6)-Methylguanine-DNA Methyltransferase | 4 | 1990 | 118 | 0.020 |
Why?
|
Photolysis | 1 | 1988 | 13 | 0.020 |
Why?
|
Face | 1 | 1989 | 114 | 0.020 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2010 | 214 | 0.020 |
Why?
|
Treatment Refusal | 1 | 2009 | 60 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2010 | 322 | 0.020 |
Why?
|
Clone Cells | 2 | 2003 | 213 | 0.020 |
Why?
|
Nitrosourea Compounds | 1 | 1988 | 9 | 0.020 |
Why?
|
RNA Probes | 1 | 2008 | 16 | 0.020 |
Why?
|
Histone Deacetylases | 1 | 2008 | 63 | 0.020 |
Why?
|
Thiosemicarbazones | 1 | 2008 | 6 | 0.020 |
Why?
|
Dermatomycoses | 1 | 1988 | 8 | 0.020 |
Why?
|
Half-Life | 1 | 2008 | 96 | 0.020 |
Why?
|
Interleukins | 1 | 1989 | 134 | 0.020 |
Why?
|
Methemoglobinemia | 1 | 2008 | 10 | 0.020 |
Why?
|
Biopsy, Needle | 1 | 1988 | 235 | 0.020 |
Why?
|
Peritonitis | 1 | 1988 | 29 | 0.020 |
Why?
|
Homeostasis | 1 | 2010 | 409 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2012 | 1056 | 0.020 |
Why?
|
Isoleucine | 1 | 2007 | 17 | 0.020 |
Why?
|
Aspartic Acid | 1 | 2007 | 64 | 0.020 |
Why?
|
Electrochemistry | 1 | 1987 | 61 | 0.020 |
Why?
|
Clinical Competence | 1 | 1993 | 751 | 0.020 |
Why?
|
Reactive Oxygen Species | 1 | 2010 | 480 | 0.020 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2010 | 229 | 0.020 |
Why?
|
Leukemia, Monocytic, Acute | 1 | 1987 | 14 | 0.020 |
Why?
|
Glucose | 1 | 2010 | 638 | 0.020 |
Why?
|
ADP-ribosyl Cyclase 1 | 1 | 2007 | 12 | 0.020 |
Why?
|
Hematology | 1 | 2007 | 29 | 0.020 |
Why?
|
Safety | 1 | 2007 | 152 | 0.020 |
Why?
|
Carcinoma, Small Cell | 1 | 1987 | 134 | 0.020 |
Why?
|
In Vitro Techniques | 3 | 1994 | 989 | 0.020 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 1991 | 378 | 0.020 |
Why?
|
Aspartate Carbamoyltransferase | 1 | 1986 | 1 | 0.020 |
Why?
|
Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing) | 1 | 1986 | 1 | 0.020 |
Why?
|
Dihydroorotase | 1 | 1986 | 1 | 0.020 |
Why?
|
Avian Myeloblastosis Virus | 1 | 1986 | 1 | 0.020 |
Why?
|
Avian Leukosis Virus | 1 | 1986 | 4 | 0.020 |
Why?
|
Antifungal Agents | 1 | 2007 | 117 | 0.020 |
Why?
|
Liver Diseases | 1 | 2008 | 238 | 0.020 |
Why?
|
Multienzyme Complexes | 1 | 1986 | 64 | 0.020 |
Why?
|
Lewis X Antigen | 1 | 2006 | 9 | 0.020 |
Why?
|
Myeloid Progenitor Cells | 1 | 2006 | 15 | 0.020 |
Why?
|
Temperature | 1 | 1987 | 396 | 0.020 |
Why?
|
PubMed | 1 | 2005 | 12 | 0.020 |
Why?
|
Teniposide | 1 | 1985 | 6 | 0.020 |
Why?
|
Genes, Regulator | 1 | 1986 | 65 | 0.020 |
Why?
|
Tongue Diseases | 1 | 1985 | 8 | 0.020 |
Why?
|
Infusion Pumps | 1 | 2005 | 25 | 0.020 |
Why?
|
Nucleic Acid Hybridization | 3 | 1992 | 245 | 0.020 |
Why?
|
Immune Tolerance | 1 | 1988 | 337 | 0.020 |
Why?
|
Cisplatin | 1 | 1987 | 612 | 0.020 |
Why?
|
Aerosols | 2 | 1997 | 44 | 0.020 |
Why?
|
DNA, Complementary | 1 | 2006 | 393 | 0.020 |
Why?
|
Work | 1 | 1985 | 16 | 0.020 |
Why?
|
Southwestern United States | 1 | 2004 | 8 | 0.020 |
Why?
|
Centrifugation, Density Gradient | 1 | 1984 | 112 | 0.020 |
Why?
|
Genes, Dominant | 2 | 1996 | 117 | 0.020 |
Why?
|
Catalase | 1 | 1984 | 48 | 0.020 |
Why?
|
Stimulation, Chemical | 1 | 1984 | 63 | 0.020 |
Why?
|
beta 2-Microglobulin | 1 | 2004 | 24 | 0.020 |
Why?
|
Granulocyte Precursor Cells | 1 | 2004 | 7 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 1 | 1995 | 2601 | 0.020 |
Why?
|
Periodontal Diseases | 2 | 1999 | 9 | 0.020 |
Why?
|
Tooth Extraction | 2 | 1999 | 10 | 0.020 |
Why?
|
Cost of Illness | 1 | 2005 | 150 | 0.020 |
Why?
|
Metalloproteins | 1 | 2004 | 16 | 0.020 |
Why?
|
Osteolysis | 1 | 1984 | 14 | 0.020 |
Why?
|
Probability | 1 | 2005 | 355 | 0.020 |
Why?
|
LIM Domain Proteins | 1 | 2004 | 25 | 0.020 |
Why?
|
Genetic Linkage | 1 | 1986 | 623 | 0.020 |
Why?
|
Cattle | 1 | 1984 | 376 | 0.020 |
Why?
|
Bone Resorption | 1 | 1984 | 41 | 0.020 |
Why?
|
Cytochalasins | 1 | 1983 | 3 | 0.020 |
Why?
|
Dose-Response Relationship, Immunologic | 1 | 1983 | 42 | 0.010 |
Why?
|
Hypercalcemia | 1 | 1984 | 59 | 0.010 |
Why?
|
Dimethyl Sulfoxide | 1 | 1983 | 38 | 0.010 |
Why?
|
T-Lymphocytes, Helper-Inducer | 1 | 1984 | 132 | 0.010 |
Why?
|
Oxygen | 1 | 1988 | 726 | 0.010 |
Why?
|
Tumor Stem Cell Assay | 2 | 1993 | 35 | 0.010 |
Why?
|
Fanconi Anemia Complementation Group A Protein | 1 | 2003 | 1 | 0.010 |
Why?
|
Fanconi Anemia Complementation Group G Protein | 1 | 2003 | 1 | 0.010 |
Why?
|
Fanconi Anemia Complementation Group C Protein | 1 | 2003 | 4 | 0.010 |
Why?
|
Fanconi Anemia Complementation Group D2 Protein | 1 | 2003 | 4 | 0.010 |
Why?
|
Procarbazine | 3 | 1990 | 40 | 0.010 |
Why?
|
Social Environment | 1 | 1985 | 188 | 0.010 |
Why?
|
Trinucleotide Repeats | 1 | 2003 | 31 | 0.010 |
Why?
|
Fanconi Anemia Complementation Group Proteins | 1 | 2003 | 8 | 0.010 |
Why?
|
Antimetabolites | 1 | 2003 | 24 | 0.010 |
Why?
|
Gastrointestinal Diseases | 1 | 1984 | 146 | 0.010 |
Why?
|
Naphthalenes | 1 | 1983 | 45 | 0.010 |
Why?
|
S Phase | 2 | 1993 | 62 | 0.010 |
Why?
|
Bleomycin | 3 | 1990 | 98 | 0.010 |
Why?
|
Allopurinol | 1 | 2003 | 80 | 0.010 |
Why?
|
Receptors, Natural Killer Cell | 1 | 2002 | 20 | 0.010 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily K | 1 | 2002 | 29 | 0.010 |
Why?
|
Confidence Intervals | 1 | 2003 | 229 | 0.010 |
Why?
|
Hematologic Tests | 1 | 2002 | 14 | 0.010 |
Why?
|
Computational Biology | 1 | 2006 | 528 | 0.010 |
Why?
|
Anemia, Refractory | 2 | 1996 | 5 | 0.010 |
Why?
|
Laparotomy | 1 | 1982 | 59 | 0.010 |
Why?
|
Feeding Behavior | 1 | 1985 | 324 | 0.010 |
Why?
|
Kidney Function Tests | 1 | 2002 | 123 | 0.010 |
Why?
|
Receptors, Immunologic | 1 | 2002 | 135 | 0.010 |
Why?
|
Ontario | 1 | 2001 | 52 | 0.010 |
Why?
|
CD13 Antigens | 1 | 2001 | 5 | 0.010 |
Why?
|
Lipoproteins | 1 | 1982 | 135 | 0.010 |
Why?
|
CD56 Antigen | 1 | 2001 | 18 | 0.010 |
Why?
|
CD2 Antigens | 1 | 2001 | 22 | 0.010 |
Why?
|
Lymph Nodes | 2 | 1982 | 533 | 0.010 |
Why?
|
Lipopolysaccharide Receptors | 1 | 2001 | 23 | 0.010 |
Why?
|
Interleukin-5 | 2 | 1993 | 36 | 0.010 |
Why?
|
Antigens, CD19 | 1 | 2001 | 39 | 0.010 |
Why?
|
Aluminum Silicates | 1 | 2001 | 2 | 0.010 |
Why?
|
Chromosomes, Artificial, Human | 1 | 2001 | 2 | 0.010 |
Why?
|
Apc8 Subunit, Anaphase-Promoting Complex-Cyclosome | 1 | 2001 | 2 | 0.010 |
Why?
|
Soil Pollutants | 1 | 2001 | 7 | 0.010 |
Why?
|
Multigene Family | 1 | 2002 | 202 | 0.010 |
Why?
|
Spleen | 1 | 1982 | 430 | 0.010 |
Why?
|
Interleukin-4 | 2 | 1993 | 127 | 0.010 |
Why?
|
Mitosis | 1 | 1981 | 153 | 0.010 |
Why?
|
Killer Cells, Natural | 1 | 2002 | 267 | 0.010 |
Why?
|
Chromosomes, Bacterial | 1 | 2000 | 29 | 0.010 |
Why?
|
Chromosomes, Human, Pair 20 | 1 | 2000 | 32 | 0.010 |
Why?
|
Amifostine | 1 | 2000 | 51 | 0.010 |
Why?
|
Ki-1 Antigen | 2 | 1990 | 17 | 0.010 |
Why?
|
Radiation-Protective Agents | 1 | 2000 | 96 | 0.010 |
Why?
|
Oxidation-Reduction | 1 | 2001 | 373 | 0.010 |
Why?
|
Cell Transformation, Viral | 2 | 1990 | 40 | 0.010 |
Why?
|
Terminology as Topic | 1 | 1981 | 217 | 0.010 |
Why?
|
Gingivitis | 1 | 1999 | 1 | 0.010 |
Why?
|
Dental Caries | 1 | 1999 | 4 | 0.010 |
Why?
|
Microfilament Proteins | 1 | 2001 | 208 | 0.010 |
Why?
|
Case Management | 1 | 1999 | 24 | 0.010 |
Why?
|
Binding Sites | 1 | 2002 | 1098 | 0.010 |
Why?
|
Herpesvirus 4, Human | 2 | 1990 | 114 | 0.010 |
Why?
|
Regression Analysis | 1 | 2000 | 596 | 0.010 |
Why?
|
Polymorphism, Single-Stranded Conformational | 1 | 1997 | 29 | 0.010 |
Why?
|
Algorithms | 1 | 2006 | 1830 | 0.010 |
Why?
|
Microscopy, Electron | 1 | 1998 | 503 | 0.010 |
Why?
|
Reference Values | 2 | 1990 | 674 | 0.010 |
Why?
|
Models, Genetic | 1 | 2003 | 926 | 0.010 |
Why?
|
Air Pollutants, Occupational | 1 | 1997 | 6 | 0.010 |
Why?
|
Carrier Proteins | 1 | 2001 | 673 | 0.010 |
Why?
|
Styrene | 1 | 1996 | 1 | 0.010 |
Why?
|
Radiotherapy Dosage | 1 | 1998 | 468 | 0.010 |
Why?
|
Laryngeal Neoplasms | 1 | 1997 | 89 | 0.010 |
Why?
|
Leucovorin | 2 | 1990 | 218 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2001 | 1991 | 0.010 |
Why?
|
Anemia, Refractory, with Excess of Blasts | 1 | 1996 | 8 | 0.010 |
Why?
|
Anemia, Sideroblastic | 1 | 1996 | 6 | 0.010 |
Why?
|
Erythropoiesis | 1 | 1996 | 52 | 0.010 |
Why?
|
Occupational Exposure | 1 | 1996 | 80 | 0.010 |
Why?
|
Vinblastine | 2 | 1988 | 108 | 0.010 |
Why?
|
Fatal Outcome | 1 | 1996 | 293 | 0.010 |
Why?
|
Prothrombin Time | 1 | 1995 | 20 | 0.010 |
Why?
|
Lung Neoplasms | 1 | 1987 | 2262 | 0.010 |
Why?
|
Receptors, Granulocyte Colony-Stimulating Factor | 1 | 1994 | 1 | 0.010 |
Why?
|
Gene Rearrangement, B-Lymphocyte, Heavy Chain | 1 | 1994 | 20 | 0.010 |
Why?
|
Chromosomes, Human, Pair 4 | 1 | 1994 | 48 | 0.010 |
Why?
|
CD4-CD8 Ratio | 1 | 1994 | 18 | 0.010 |
Why?
|
Receptors, Interleukin-2 | 1 | 1994 | 66 | 0.010 |
Why?
|
Colony-Forming Units Assay | 1 | 1994 | 40 | 0.010 |
Why?
|
Hematocrit | 1 | 1994 | 68 | 0.010 |
Why?
|
Restriction Mapping | 1 | 1993 | 157 | 0.010 |
Why?
|
Interleukin-9 | 1 | 1993 | 3 | 0.010 |
Why?
|
Transcription Factor CHOP | 1 | 1993 | 15 | 0.010 |
Why?
|
Interleukin-3 | 1 | 1993 | 36 | 0.010 |
Why?
|
Arabinofuranosylcytosine Triphosphate | 1 | 1993 | 1 | 0.010 |
Why?
|
Cell Count | 1 | 1994 | 195 | 0.010 |
Why?
|
Cryopreservation | 1 | 1994 | 69 | 0.010 |
Why?
|
Medical Audit | 1 | 1993 | 41 | 0.010 |
Why?
|
Chest Tubes | 1 | 1993 | 23 | 0.010 |
Why?
|
Transformation, Genetic | 1 | 1993 | 40 | 0.010 |
Why?
|
RNA-Binding Protein FUS | 1 | 1993 | 11 | 0.010 |
Why?
|
Aircraft | 1 | 1993 | 20 | 0.010 |
Why?
|
Blood Cells | 1 | 1993 | 33 | 0.010 |
Why?
|
Heterogeneous-Nuclear Ribonucleoproteins | 1 | 1993 | 19 | 0.010 |
Why?
|
Acetates | 2 | 1983 | 66 | 0.010 |
Why?
|
Copper | 1 | 1993 | 71 | 0.010 |
Why?
|
Tritium | 1 | 1992 | 133 | 0.010 |
Why?
|
Bromodeoxyuridine | 1 | 1992 | 57 | 0.010 |
Why?
|
Proto-Oncogene Proteins c-myb | 1 | 1992 | 9 | 0.010 |
Why?
|
Trauma Centers | 1 | 1993 | 116 | 0.010 |
Why?
|
Polymorphism, Restriction Fragment Length | 1 | 1992 | 147 | 0.010 |
Why?
|
Fungi | 1 | 1992 | 65 | 0.010 |
Why?
|
Nucleic Acid Conformation | 1 | 1993 | 332 | 0.010 |
Why?
|
Interphase | 1 | 1991 | 34 | 0.010 |
Why?
|
Fluorescent Dyes | 1 | 1992 | 242 | 0.010 |
Why?
|
X Chromosome | 1 | 1991 | 152 | 0.010 |
Why?
|
Saccharomyces cerevisiae | 1 | 1993 | 434 | 0.010 |
Why?
|
Genes, Immunoglobulin | 1 | 1990 | 111 | 0.010 |
Why?
|
Lymphoma, Follicular | 1 | 1990 | 70 | 0.010 |
Why?
|
Homozygote | 1 | 1990 | 200 | 0.010 |
Why?
|
Methylnitronitrosoguanidine | 1 | 1989 | 16 | 0.010 |
Why?
|
Amino Acid Sequence | 1 | 1993 | 2062 | 0.010 |
Why?
|
Centromere | 1 | 1988 | 26 | 0.010 |
Why?
|
Mechlorethamine | 1 | 1988 | 11 | 0.010 |
Why?
|
Peritoneal Dialysis, Continuous Ambulatory | 1 | 1988 | 10 | 0.010 |
Why?
|
Metaphase | 1 | 1987 | 25 | 0.000 |
Why?
|
Dacarbazine | 1 | 1988 | 102 | 0.000 |
Why?
|
Rectal Neoplasms | 1 | 1988 | 116 | 0.000 |
Why?
|
Fingers | 1 | 1987 | 68 | 0.000 |
Why?
|
Chromosomes, Human, 19-20 | 1 | 1986 | 5 | 0.000 |
Why?
|
DNA Restriction Enzymes | 1 | 1986 | 98 | 0.000 |
Why?
|
Personality | 1 | 1988 | 134 | 0.000 |
Why?
|
Leukocytes | 1 | 1987 | 202 | 0.000 |
Why?
|
Attitude to Health | 1 | 1988 | 220 | 0.000 |
Why?
|
Dental Pulp Diseases | 1 | 1986 | 2 | 0.000 |
Why?
|
Molecular Weight | 1 | 1986 | 332 | 0.000 |
Why?
|
Hybrid Cells | 1 | 1986 | 72 | 0.000 |
Why?
|
Statistics as Topic | 1 | 1987 | 238 | 0.000 |
Why?
|
Mitosporic Fungi | 1 | 1985 | 3 | 0.000 |
Why?
|
Neoplasms, Multiple Primary | 1 | 1986 | 100 | 0.000 |
Why?
|
Ischemia | 1 | 1987 | 243 | 0.000 |
Why?
|
Radiation Injuries | 1 | 1986 | 155 | 0.000 |
Why?
|
Syndrome | 1 | 1985 | 446 | 0.000 |
Why?
|
Histocytochemistry | 1 | 1984 | 130 | 0.000 |
Why?
|
Staining and Labeling | 1 | 1984 | 165 | 0.000 |
Why?
|
Retroviridae Infections | 1 | 1984 | 48 | 0.000 |
Why?
|
Optical Rotation | 1 | 1983 | 2 | 0.000 |
Why?
|
Hydroxycholesterols | 1 | 1983 | 6 | 0.000 |
Why?
|
Kidney Failure, Chronic | 1 | 1988 | 509 | 0.000 |
Why?
|
Monocytes | 1 | 1983 | 214 | 0.000 |
Why?
|